Skip to content

About
Science
Newsroom
Careers
Contact

Menu

About
Science
Newsroom
Careers
Contact

Press Releases

Newsroom

Menu

Current News
Press Releases
Media
Scientific Publications

2022

Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day

April 28, 2022

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

April 21, 2022

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research

April 7, 2022

2021

Fierce Biotech Names Tvardi Therapeutics as One of its “Fierce 15” Biotech Companies of 2021

September 27, 2021

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

June 23, 2021

Tvardi Therapeutics Appoints Michael Wyzga, Former CFO of Genzyme, to Board of Directors

March 11, 2021

Tvardi Therapeutics Appoints Sujal Shah to Board of Directors

January 28, 2021

2020

Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum

November 12, 2020

Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research

July 24, 2020

2019

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers

March 13, 2019

2018

Tvardi Therapeutics names Imran Alibhai Chief Executive Officer

December 12, 2018

Tvardi’s Scientific Advisory Board Member, Dr. Jim Allison, Wins Nobel

October 1, 2018

Tvardi Announces Series A Financing

September 20, 2018

Home
About
Our Science
Newsroom
Contact
FCOI
Privacy Policy
Terms of Use

Menu

Home
About
Our Science
Newsroom
Contact
FCOI
Privacy Policy
Terms of Use

Home
About
Our Science
Newsroom
Contact
FCOI
Privacy Policy
Terms of Use

Menu

Home
About
Our Science
Newsroom
Contact
FCOI
Privacy Policy
Terms of Use

Linkedin Twitter

Tvardi Therapeutics ©2022

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and Terms of Use.